Table 1.
Baseline characteristics for patients and controls.
| Parameter | Total (n = 288) |
Patients (n = 189) |
Controls (n = 99) |
|---|---|---|---|
| BMI, Median (min, max) | 25.2 (17.6, 51.3) | 24.9 (17.6, 51.3) | 25.4 (17.9, 45.7) |
| N of comorbidities, Median (min, max) | 0.00 (0.00, 4.0) | 1.00 (0.00, 4.0) | 0.00 (0.00, 2.0) |
| n (%) | n (%) | n (%) | |
| Gender | |||
| Male | 124 (43.1) | 87 (46.0) | 37 (37.4) |
| Female | 164 (56.9) | 102 (54.0) | 62 (62.6) |
| Age | |||
| 18–29 | 5 (1.7) | 1 (0.53) | 4 (4.0) |
| 30–39 | 28 (9.7) | 3 (1.6) | 25 (25.3) |
| 40–49 | 57 (19.8) | 25 (13.2) | 32 (32.3) |
| 50–59 | 64 (22.2) | 39 (20.6) | 25 (25.3) |
| 60–69 | 60 (20.8) | 51 (27.0) | 9 (9.1) |
| 70–79 | 56 (19.4) | 52 (27.5) | 4 (4.0) |
| 80–85 | 15 (5.2) | 15 (7.9) | 0 (0.0) |
| >85 | 3 (1.0) | 3 (1.6) | 0 (0.0) |
| BMI | |||
| Underweight | 7 (2.4) | 5 (2.6) | 2 (2.0) |
| Normal | 134 (46.5) | 91 (48.1) | 43 (43.4) |
| Obese | 53 (18.4) | 38 (20.1) | 15 (15.2) |
| Overweight | 94 (32.6) | 55 (29.1) | 39 (39.4) |
| Smoking Status | |||
| Never smoker | 124 (43.1) | 82 (43.4) | 42 (42.4) |
| Current smoker | 88 (30.6) | 50 (26.5) | 38 (38.4) |
| Previous smoker—stopped within the last 10 years | 71 (24.7) | 53 (28.0) | 18 (18.2) |
| Not Reported | 5 (1.7) | 4 (2.1) | 1 (1.0) |
| Comorbidities | |||
| No | 168 (58.3) | 91 (48.1) | 77 (77.8) |
| Yes | 120 (41.7) | 98 (51.9) | 22 (22.2) |
| Vaccine administered | |||
| BNT162b2 (Pfizer) | 262 (91.0) | 163 (86.2) | 99 (100.0) |
| mRNA-1273 (Moderna) | 19 (6.6) | 19 (10.1) | 0 (0.0) |
| AZD1222 (Astra Zeneca) | 7 (2.4) | 7 (3.7) | 0 (0.0) |
| Autoimmune disease | |||
| No | 266 (92.4) | 184 (97.4) | 82 (82.8) |
| Active autoimmune disease | 17 (5.9) | 3 (1.6) | 14 (14.1) |
| Inactive autoimmune disease | 4 (1.4) | 1 (0.53) | 3 (3.0) |
| Not Reported | 1 (0.35) | 1 (0.53) | 0 (0.0) |
| Cancer type (primary cancer diagnosis) | |||
| Breast cancer | 51 (27.0) | 51 (27.0) | ---- |
| NSCLC | 37 (19.6) | 37 (19.6) | ---- |
| SCLC | 20 (10.6) | 20 (10.6) | ---- |
| Mesothelioma | 1 (0.53) | 1 (0.53) | ---- |
| Head and Neck cancer | 1 (0.53) | 1 (0.53) | ---- |
| Stomach cancer | 6 (3.2) | 6 (3.2) | ---- |
| Pancreatic cancer | 11 (5.8) | 11 (5.8) | ---- |
| Colorectal cancer | 27 (14.3) | 27 (14.3) | ---- |
| Ovarian cancer | 11 (5.8) | 11 (5.8) | ---- |
| Other Gynecological cancer | 1 (0.53) | 1 (0.53) | ---- |
| Bladder cancer | 4 (2.1) | 4 (2.1) | ---- |
| Prostate cancer | 4 (2.1) | 4 (2.1) | ---- |
| Kidney cancer | 4 (2.1) | 4 (2.1) | ---- |
| Testicular cancer | 1 (0.53) | 1 (0.53) | ---- |
| Melanoma | 3 (1.6) | 3 (1.6) | ---- |
| Other * | 7 (3.7) | 7 (3.7) | ---- |
| Performance Status | |||
| 0 | 157 (83.1) | 157 (83.1) | ---- |
| 1 | 32 (16.9) | 32 (16.9) | ---- |
| Concomitant Corticosteroid use | |||
| No | 179 (94.7) | 179 (94.7) | ---- |
| Yes | 10 (5.3) | 10 (5.3) | ---- |
| Active antineoplastic treatment | |||
| No | 27 (14.3) | 27 (14.3) | ---- |
| Yes | 162 (85.7) | 162 (85.7) | ---- |
| Type of antineoplastic treatment | |||
| Chemotherapy | 89 (54.9) | 89 (54.9) | ---- |
| Immunotherapy only | 32 (19.8) | 32 (19.8) | ---- |
| Chemo-immunotherapy combination | 12 (7.4) | 12 (7.4) | ---- |
| Targeted agent, TKI only | 4 (2.5) | 4 (2.5) | ---- |
| Other biologic therapy only | 21 (13.0) | 21 (13.0) | ---- |
| Endocrine therapy only | 2 (1.2) | 2 (1.2) | ---- |
| Radiotherapy only | 2 (1.2) | 2 (1.2) | ---- |
| Cancer status at vaccination | |||
| Primary recently operated | 45 (23.8) | 45 (23.8) | ---- |
| Recurrent | 49 (25.9) | 49 (25.9) | ---- |
| Metastatic | 89 (47.1) | 89 (47.1) | ---- |
| Other | 6 (3.2) | 6 (3.2) | ---- |
n, number; BMI, body mass index; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer. * Neuroendocrine lung cancer (n = 1), Cancer of Unknown Primary (n = 2), Anal Cancer (n = 1), GIST small intestine (n = 1), GIST large intestine (n = 2).